Merck KGaA (OTCMKTS:MKKGY) Short Interest Update
by Renee Jackson · The Cerbat GemMerck KGaA (OTCMKTS:MKKGY – Get Free Report) was the recipient of a large drop in short interest in April. As of April 30th, there was short interest totaling 75,400 shares, a drop of 42.1% from the April 15th total of 130,134 shares. Based on an average daily volume of 198,917 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the shares of the stock are sold short.
Analyst Upgrades and Downgrades
MKKGY has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft cut Merck KGaA from a “buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Sanford C. Bernstein upgraded Merck KGaA to a “hold” rating in a report on Thursday, March 19th. Four equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.
View Our Latest Analysis on Merck KGaA
Merck KGaA Price Performance
OTCMKTS:MKKGY traded down $0.91 during trading hours on Friday, reaching $27.17. 67,678 shares of the company traded hands, compared to its average volume of 96,962. The firm’s 50-day moving average is $25.92 and its 200-day moving average is $27.55. The stock has a market cap of $17.56 billion, a P/E ratio of 12.08, a P/E/G ratio of 2.45 and a beta of 0.97. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.46 and a quick ratio of 0.96. Merck KGaA has a 1-year low of $23.73 and a 1-year high of $31.00.
Merck KGaA (OTCMKTS:MKKGY – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.14. The firm had revenue of $6.03 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Merck KGaA had a return on equity of 8.93% and a net margin of 12.07%. Equities research analysts expect that Merck KGaA will post 1.83 earnings per share for the current fiscal year.
Merck KGaA Company Profile
Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.
Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.